Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

San Giovanni Rotondo (FG), Italy Clinical Trials

A listing of San Giovanni Rotondo (FG), Italy clinical trials actively recruiting patients volunteers.

RESULTS

Found (93) clinical trials

Stroke Rehabilitation With Exoskeleton-assisted Gait.

*Procedures During Screening Process: This multicentric study will involve recruitment of individuals who have experienced a middle to severe stroke as well as patients with similar neurological weakness from the inpatient setting, outpatient clinics, as well as day rehabilitation sites through all the health institutes participating to this study project. ...

Phase N/A

0.0 miles

Learn More »

Assess the Anti-Tumor Activity and Safety of REGN1979 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Primary objective is to assess the anti-tumor activity of single agent REGN1979 as measured by the objective response rate (ORR) according to the Lugano Classification of response in malignant lymphoma (Cheson, 2014) and as assessed by independent central review in each of the following B-cell non-Hodgkin lymphoma (B-NHL) subgroups: In ...

Phase

0.0 miles

Learn More »

Lenalidomide Monotherapy in R/R DLBCL

Tafasitamab (MOR00208) is currently in development for the treatment of R/R DLBCL. An ongoing, single-arm, phase II, open label, multicenter study (MOR208C203) is evaluating the efficacy and safety of tafasitamab combined with lenalidomide in patients with R/R DLBCL. In order to establish a lenalidomide monotherapy as a control cohort, this ...

Phase N/A

0.0 miles

Learn More »

Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN)

This observational study has been planned to evaluate the effectiveness of obinutuzumab in combination with chemotherapy in previously untreated advanced FL patients, in the real world setting in Italy. The study will allow to collect real-life data in a significant number of Italian patients when compared to participants in pivotal ...

Phase N/A

0.0 miles

Learn More »

Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients

The Part A of the study is currently not accepting healthy volunteers as the recruitment for the part A has completed.

Phase

0.0 miles

Learn More »

Rituximab Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL

The aim of the study is to improve long term results of R-BAC, consolidating patients with high-risk (HR) features (defined as: elevated Ki67 and/or blastoid cytology and/or TP53 mutation after central pathology review) with Venetoclax (ABT-199), which has demonstrated relevant single agent activity in relapsed/refractory MCL in a Phase 1-2 ...

Phase

0.0 miles

Learn More »

Puglia HCV Micro-elimination Program

Scientific Rationale: To adhere to the WHO plan of identifying 90% and treat 80% of HCV infected subjects, in several Countries a number of barriers need to be overcome (1). A focused effort from physicians and public administrative authorities is required to increase HCV treatment rates using direct acting antivirals ...

Phase N/A

0.0 miles

Learn More »

Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System

Primary central nervous system lymphomas (PCNSL) are rare aggressive malignancies, mostly of B-cell origin, representing 4% of intracranial neoplasms and 4-6% of extranodal non-Hodgkin's lymphomas (NHL). Despite improvements in treatment, PCNSL is associated with an aggressive course and unsatisfactory outcome. The median age at diagnosis is 61 years and age ...

Phase

0.0 miles

Learn More »

A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI) Immunomodulatory Drug (IMID) and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment

The purpose of this study is to assess the safety and clinical response including overall response rate (ORR) of real-life standard-of-care (SOC) treatments under routine clinical practice, over a 24-month period, in patients with relapsed/refractory multiple myeloma (RRMM).

Phase N/A

0.0 miles

Learn More »

The purpose of this study is to evaluate the overall response rate (ORR) of INCB054828 as a monotherapy in the treatment of metastatic or surgically unresectable urothelial carcinoma harboring FGF/FGFR alterations.

Phase

0.0 miles

Learn More »